Kosiborod MN, Esterline R, Furtado RHM, et al. - Receiving treatment with dapagliflozin did not correlate with a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery in patients with cardiometabolic risk factors (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease) who were hospitalized with COVID-19.

• A randomized, double-blind, placebo-controlled trial, named DARE-19, was performed including patients hospitalized with COVID-19 and with at least one cardiometabolic risk factor.

• A total of 1,250 patients were randomly assigned to receive either dapagliflozin (10 mg daily orally) or matched placebo for 30 days.

• Treatment with dapagliflozin was well tolerated.